menu
    • menu
    [{"orgOrder":0,"company":"Pregene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"BCMA CAR-NK Cell","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pregene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pregene \/ Undisclosed"},{"orgOrder":0,"company":"Pregene","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"PRG1801","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Pregene","amount2":0.16,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"Infusion","sponsorNew":"Pregene \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Pregene \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Pregene","sponsor":"Pregene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"ESO-T01","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pregene \/ Pregene","highestDevelopmentStatusID":"6","companyTruncated":"Pregene \/ Pregene"},{"orgOrder":0,"company":"Pregene","sponsor":"Pregene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"ESO-T01","moa":"BCMA receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pregene \/ Pregene","highestDevelopmentStatusID":"6","companyTruncated":"Pregene \/ Pregene"},{"orgOrder":0,"company":"Pregene","sponsor":"Bone Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2022","type":"Termination","leadProduct":"Allogeneic Bone-Forming Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Pregene","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Pregene \/ Pregene","highestDevelopmentStatusID":"8","companyTruncated":"Pregene \/ Pregene"},{"orgOrder":0,"company":"Pregene","sponsor":"Pregene","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PRG-1801","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pregene \/ Pregene","highestDevelopmentStatusID":"6","companyTruncated":"Pregene \/ Pregene"},{"orgOrder":0,"company":"Pregene","sponsor":"Pregene","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PRG-1801","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pregene \/ Pregene","highestDevelopmentStatusID":"6","companyTruncated":"Pregene \/ Pregene"},{"orgOrder":0,"company":"Pregene","sponsor":"Pregene","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PRG-1801","moa":"Undisclosed","graph1":"Nephrology","graph2":"Undisclosed","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pregene \/ Pregene","highestDevelopmentStatusID":"1","companyTruncated":"Pregene \/ Pregene"},{"orgOrder":0,"company":"Pregene","sponsor":"Pregene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PRG2302","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pregene \/ Pregene","highestDevelopmentStatusID":"6","companyTruncated":"Pregene \/ Pregene"},{"orgOrder":0,"company":"Pregene","sponsor":"Pregene","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PRG-2311","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase I","graph3":"Pregene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pregene \/ Pregene","highestDevelopmentStatusID":"6","companyTruncated":"Pregene \/ Pregene"}]

    Find Clinical Drug Pipeline Developments & Deals by Pregene

    Menu

    Pregene

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pregene

                            China arrow
                            Fall Technical Meeting
                            Not Confirmed

                            Pregene

                            China arrow
                            Fall Technical Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ESO-T01

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Chunrui Li

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma

                            Details : ESO-T01 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Multiple Myeloma.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            January 24, 2025

                            Lead Product(s) : ESO-T01

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Chunrui Li

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pregene

                            China arrow
                            Fall Technical Meeting
                            Not Confirmed

                            Pregene

                            China arrow
                            Fall Technical Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ESO-T01

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Wuhan Union Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myelo...

                            Details : ESO-T01 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Multiple Myeloma.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            November 15, 2024

                            Lead Product(s) : ESO-T01

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Wuhan Union Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Pregene

                            China arrow
                            Fall Technical Meeting
                            Not Confirmed

                            Pregene

                            China arrow
                            Fall Technical Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRG2302

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Tan Jie

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.

                            Details : PRG2302 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 26, 2024

                            Lead Product(s) : PRG2302

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Tan Jie

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Pregene

                            China arrow
                            Fall Technical Meeting
                            Not Confirmed

                            Pregene

                            China arrow
                            Fall Technical Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRG-1801

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Recipient : Wuhan Union Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of PRG-1801 in Recurrent/Refractory Immune Thrombocytopenia (ITP)

                            Details : PRG-1801 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Purpura, Thrombocytopenic, Idiopathic.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 25, 2024

                            Lead Product(s) : PRG-1801

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Recipient : Wuhan Union Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Pregene

                            China arrow
                            Fall Technical Meeting
                            Not Confirmed

                            Pregene

                            China arrow
                            Fall Technical Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRG-1801

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Recipient : Tongji Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease

                            Details : PRG-1801 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lupus Nephritis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 11, 2024

                            Lead Product(s) : PRG-1801

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Recipient : Tongji Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Pregene

                            China arrow
                            Fall Technical Meeting
                            Not Confirmed

                            Pregene

                            China arrow
                            Fall Technical Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRG-2311

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Recipient : Tongji Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease

                            Details : PRG-2311 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lupus Nephritis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 11, 2024

                            Lead Product(s) : PRG-2311

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Recipient : Tongji Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Pregene

                            China arrow
                            Fall Technical Meeting
                            Not Confirmed

                            Pregene

                            China arrow
                            Fall Technical Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRG-1801

                            Therapeutic Area : Nephrology

                            Study Phase : Undisclosed

                            Recipient : Lingli Dong

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells

                            Details : PRG-1801 is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Lupus Nephritis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 26, 2024

                            Lead Product(s) : PRG-1801

                            Therapeutic Area : Nephrology

                            Highest Development Status : Undisclosed

                            Recipient : Lingli Dong

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Pregene

                            China arrow
                            Fall Technical Meeting
                            Not Confirmed

                            Pregene

                            China arrow
                            Fall Technical Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BCMA CAR-NK Cell

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study of the Safety and Efficacy of BCMA CAR-NK

                            Details : BCMA CAR-NK Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Multiple Myeloma.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            December 15, 2022

                            Lead Product(s) : BCMA CAR-NK Cell

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Pregene

                            China arrow
                            Fall Technical Meeting
                            Not Confirmed

                            Pregene

                            China arrow
                            Fall Technical Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic Osteoblastic Cell,Allogeneic Bone-Forming Cell

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase II

                            Recipient : Bone Therapeutics

                            Deal Size : $53.6 million

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Bone Therapeutics to Regain Worldwide Rights to ALLOB

                            Details : ALLOB (allogeneic bone cell therapy) is an allogeneic osteoblastic cell therapy product derived from ex vivo cultured bone marrow cells. It represents a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells into bo...

                            Product Name : ALLOB

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : $9.7 million

                            October 07, 2022

                            Lead Product(s) : Allogeneic Osteoblastic Cell,Allogeneic Bone-Forming Cell

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase II

                            Recipient : Bone Therapeutics

                            Deal Size : $53.6 million

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Pregene

                            China arrow
                            Fall Technical Meeting
                            Not Confirmed

                            Pregene

                            China arrow
                            Fall Technical Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRG1801

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Dr. Reddy\'s Laboratories

                            Deal Size : $162.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Pregene and Dr. Reddy's Announce License Agreement for Anti-BCMA CAR-T PRG1801 in India

                            Details : Shenzhen Pregene Biopharma and Dr. Reddy's Laboratories announce a license agreement whereby Dr Reddy's will acquire the exclusive rights in India for PRG1801, an anti-BCMA CAR-T cell therapy injection based on single domain antibody technology.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 13, 2021

                            Lead Product(s) : PRG1801

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Dr. Reddy\'s Laboratories

                            Deal Size : $162.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth